Jefferies Global Healthcare Conference
Logotype for Definium Therapeutics Inc

Definium Therapeutics (DFTX) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Definium Therapeutics Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

DT120 clinical progress and regulatory plans

  • Proprietary ODT form of LSD; three positive pivotal readouts over the summer across GAD and MDD, with management citing the largest pivotal-study effect in each indication for a single dose.

  • Fourth pivotal study, the second in MDD, expected to read out in 2027; NDA filing targeted for H1 2027.

  • Filing routes under consideration include joint GAD/MDD submission, GAD first followed by an MDD sNDA, or staggered submissions potentially timed for a joint launch; pre-NDA meeting planned for Q4.

  • Breakthrough Therapy designation for both programs; frequent FDA dialogue and NDA compilation underway after pivotal work begun in Jan 2022.

Dose profile and care model

  • Retreatment is expected when symptoms return; the nine-month extension allowed up to four open-label doses for return of moderate-or-worse symptoms.

  • Data through six months showed ~25% with lasting benefit after one dose and ~one-third requiring a second; most patients appeared to fall in the one-to-three-dose range.

  • Trial observation averaged six hours, converging from a five-to-eight-hour range; one person was typically in the room with the patient, with a second staffer monitoring by video.

  • Most trial monitors were licensed clinical social workers; more open-label data expected in the near future.

  • Single dose is 100 mcg; management said accrued supply is more than sufficient for NDA filing needs.

Market and launch opportunity

  • Estimated U.S. population with GAD or MDD is 50m; management’s treatment funnel implies ~4m patients eligible for a step-three therapy after diagnosis, treatment and multiple drug failures.

  • SPRAVATO was cited as an analog at ~$2bn annual revenue and $30k-$70k annual pricing, with a ~$50k midpoint; it can involve up to 56 doses a year versus a few expected for DT120.

  • Management sees potential to launch DT120 for both GAD and MDD, and described treatment centers as integrating multiple interventions and adaptable to new modalities.

  • Management said Usona’s psilocybin filing would not set a negative pricing precedent, citing distinct programs and a focus on resourcing responsible delivery.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Definium Therapeutics